<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33786588</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1528-0020</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>137</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Blood</Title>
          <ISOAbbreviation>Blood</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib in treatment-naive chronic lymphocytic leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>3327</StartPage>
          <EndPage>3338</EndPage>
          <MedlinePgn>3327-3338</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2020009617</ELocationID>
        <Abstract>
          <AbstractText>Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). Adults were eligible for enrollment if chemotherapy was declined or deemed inappropriate due to comorbidities (N = 99). Patients had a median age of 64 years and 47% had Rai stage III/IV disease. Acalabrutinib was administered orally 200 mg once daily, or 100 mg twice daily until progression or intolerance. A total of 99 patients were treated; 57 (62%) had unmutated immunoglobulin heavy-chain variable gene, and 12 (18%) had TP53 aberrations. After median follow-up of 53 months, 85 patients remain on treatment; 14 discontinued treatment, mostly because of adverse events (AEs) (n = 6) or disease progression (n = 3). Overall response rate was 97% (90% partial response; 7% complete response), with similar outcomes among all prognostic subgroups. Because of improved trough BTK occupancy with twice-daily dosing, all patients were transitioned to 100 mg twice daily. Median duration of response (DOR) was not reached; 48-month DOR rate was 97% (95% confidence interval, 90-99). Serious AEs were reported in 38 patients (38%). AEs required discontinuation in 6 patients (6%) because of second primary cancers (n = 4) and infection (n = 2). Grade ≥3 events of special interest included infection (15%), hypertension (11%), bleeding events (3%), and atrial fibrillation (2%). Durable efficacy and long-term safety of acalabrutinib in this trial support its use in clinical management of symptomatic, untreated patients with CLL.</AbstractText>
          <CopyrightInformation>© 2021 by The American Society of Hematology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Byrd</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woyach</LastName>
            <ForeName>Jennifer A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Furman</LastName>
            <ForeName>Richard R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Brien</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Jennifer R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Dana-Farber Cancer Institute, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stephens</LastName>
            <ForeName>Deborah M</ForeName>
            <Initials>DM</Initials>
            <Identifier Source="ORCID">0000-0001-9188-5008</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Utah Huntsman Cancer Institute, Salt Lake City, UT.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barrientos</LastName>
            <ForeName>Jacqueline C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Devereux</LastName>
            <ForeName>Stephen</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>College Hospital, NHS Foundation Trust Denmark Hill, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hillmen</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-5617-4403</Identifier>
            <AffiliationInfo>
              <Affiliation>St James's University Hospital, Leeds, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pagel</LastName>
            <ForeName>John M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Swedish Cancer Institute, Seattle, WA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min Hui</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>AstraZeneca, South San Francisco, CA; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jain</LastName>
            <ForeName>Nitin</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wierda</LastName>
            <ForeName>William G</ForeName>
            <Initials>WG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA016058</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA197734</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Blood</MedlineTA>
        <NlmUniqueID>7603509</NlmUniqueID>
        <ISSNLinking>0006-4971</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Blood. 2021 Jun 17;137(24):3313-3314</RefSource>
          <PMID Version="1">34137848</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="Y">Benzamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="Y">Pyrazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33786588</ArticleId>
        <ArticleId IdType="pmc">PMC8670015</ArticleId>
        <ArticleId IdType="doi">10.1182/blood.2020009617</ArticleId>
        <ArticleId IdType="pii">S0006-4971(21)00755-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute 2019. Available at: https://seer.cancer.gov/csr/1975_2016/. Accessed 22 December, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>
Hoechstetter MA, Busch R, Eichhorst B, et al. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017;31(12):2833-2837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28804126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mellemgaard A, Geisler CH, Storm HH. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia. Eur J Haematol. 1994;53(4):218-222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7957806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol. 1998;25(1):98-106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9482531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107(2):742-751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16179374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
International CLL-IPI working group . An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27185642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dufour A, Palermo G, Zellmeier E, et al. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood. 2013;121(18):3650-3657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23525797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11136261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10477713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hallek M, Fischer K, Fingerle-Rowson G, et al; German Chronic Lymphocytic Leukaemia Study Group . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a ran‐domised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Michallet AS, Aktan M, Hiddemann W, et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018;103(4):698-706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5865431</ArticleId>
            <ArticleId IdType="pubmed">29419437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247-3254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24652989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3772525</ArticleId>
            <ArticleId IdType="pubmed">23782158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921964</ArticleId>
            <ArticleId IdType="pubmed">29437592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators . Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2919935</ArticleId>
            <ArticleId IdType="pubmed">20615965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240-252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849-2861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32459600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharman JPE, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8151619</ArticleId>
            <ArticleId IdType="pubmed">32305093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204-1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146022</ArticleId>
            <ArticleId IdType="pubmed">31876911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3410400</ArticleId>
            <ArticleId IdType="pubmed">22778323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.</Citation>
        </Reference>
        <Reference>
          <Citation>
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1139039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30522969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052-3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5531425</ArticleId>
            <ArticleId IdType="pubmed">28714866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71-83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3555194</ArticleId>
            <ArticleId IdType="pubmed">23359016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Bojnik E, Ruppert AS, et al. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8):1207-1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3931190</ArticleId>
            <ArticleId IdType="pubmed">24311722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun C, Nierman P, Kendall EK, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136(1):93-105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7332900</ArticleId>
            <ArticleId IdType="pubmed">32202637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Williams AM, Baran AM, Schaffer M, et al. Significant weight gain in CLL patients treated with ibrutinib: a potentially deleterious consequence of therapy. Am J Hematol. 2020;95(1):E16-E18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7967863</ArticleId>
            <ArticleId IdType="pubmed">31621100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799-1807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6595265</ArticleId>
            <ArticleId IdType="pubmed">31196847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787-798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7214263</ArticleId>
            <ArticleId IdType="pubmed">31628428</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
